Menu
Recruiting NCT07293689

PREcision MEDicine In Achalasia (PREMEDIA) - Cohort

Observational Type III Achalasia EGJ Outflow Obstruction With Spastic/Hypercontractile Features Jackhammer Esophagus Distal Esophageal Spasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Type III Achalasia, EGJ Outflow Obstruction With Spastic/Hypercontractile Features, Jackhammer Esophagus, Distal Esophageal Spasm. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

PREcision MEDicine In Achalasia - A Multicenter Randomized Non-Inferiority Clinical Trial of Short Tailored POEM vs. Standard POEM for Non-Spastic Achalasia and A Multicenter Prospective Cohort Study of Long Tailored POEM for Spastic Esophageal Motility Disorders

Overview

The goal of this observational study is to learn about how the doctor decides how long to cut t the esophageal muscle during Per-Oral Endoscopic Myotomy (POEM) in patients with difficulty swallowing due to certain conditions. The main question it aims to answer is: does pre-POEM testing help the physician choose how long to cut the muscle. Participants will allow researchers to access their standard of care information in their medical record, complete questionnaires at up to 6 times over a 2-year period.

Primary outcome measures

  • Clinical Response-Overall [Time frame: From enrollment to Year 2]
  • Clinical Response-by Sex [Time frame: From enrollment to Year 2]
  • Clinical Response-by Race [Time frame: From Enrollment to Year 2]
  • Clinical Response-by Ethnicity [Time frame: From Enrollment to Year 2]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18
  • Type III achalasia or EGJOO with spastic/hypercontractile features or Jackhammer Esophagus or Distal Esophageal Spasm
  • Eckardt Score > 3

Exclusion criteria

  • Exclusion:
  • Prior POEM
  • Prior surgical treatment for achalasia
  • Endoscopic pneumatic dilation or lower esophageal sphincter botulinum toxin (botox) injection within 6 months
  • Prior unrelated esophageal or upper gastric surgery, including Roux-en-Y gastric bypass and sleeve gastrectomy
  • Prior endoscopic gastroesophageal intervention for obesity or GERD, such endoscopic sleeve gastroplasty or transoral incisionless fundoplication
  • Known secondary achalasia related to malignancy (pseudoachalasia)
  • Known eosinophilic esophagitis
  • Diverticulum (> 2 cm) in distal esophagus
  • Megaesophagus
  • Fibroinflammatory stricture of the esophagus due to any etiology (e.g., peptic, radiation, eosinophilic)
  • Pregnancy
  • Standard contraindications to general anesthesia
  • Standard contraindications to endoscopic myotomy in the esophagus (e.g. untreated varices)
  • Unwillingness or inability to consent for the study
  • Anticipated inability to follow protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

United States · 15 centers
  • Mayo Clinic Arizona — Scottsdale
  • University of California San Diego — La Jolla
  • University of Colorado Denver — Denver
  • University of Florida — Gainesville
  • Adventist Health System/Sunbelt, Inc — Orlando
  • Emory University — Atlanta
  • Northwestern University — Chicago
  • Johns Hopkins University — Baltimore
  • … and 7 more centers

Identifiers

NCT: NCT07293689 · PREMEDIA (Pro00083748) - 02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗